FindTrial
Sign In

Compassionate Use or Expanded Access of Dupilumab

Unapproved Dupilumab Indications for Potential Compassionate Use or Expanded Access

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT04776694
Enrollment
Unknown
Registered
2021-03-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Inflammatory Disorders

Keywords

Allergies, Hand and Foot Dermatits, Eosinophilic Esophagitis (EoE) - Pediatrics, Hailey-Hailey Disease, Nasal Polysposis (NP), Idiopathic Urticaria, Dermal Hypersensitivity Reaction, Eosinophilic Gastrointestinal Disease (EGID), Actinic Prurigo, Eosinophilic Cystitis, Allergic Rhinitis with Nasal Polyposis, Epidermolysis Bullousa Simplex (EBS), Chronic Spontaneous Urticaria (CSU), Cicatricial Pemphigoid, Pemphigus Foliaceus, Disseminated Coccidiomycosis, Topical steroid withdrawal syndrome, Middle ear disease, Eosinophilic Enterocolitis

Brief summary

Provide Compassionate Use or Expanded Access of Dupilumab

Detailed description

Compassionate Use or Expanded Access requests are only being considered in response to Individual Patient or Treatment Investigational New Drug (IND) applications. Availability will depend on location.

Interventions

DRUGDupilumab

To be provided by Regeneron

Sponsors

Regeneron Pharmaceuticals
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
6 Months to No maximum

Inclusion criteria

Eligibility will be determined during the application review process.

Contacts

CONTACTRequests must be initiated by a treating physician. Physicians should contact
compassionateuserequests@regeneron.com844-734-6643

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026